Novo Nordisk Profit Margin 2006-2019 | NVO

Current and historical gross margin, operating margin and net profit margin for Novo Nordisk (NVO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Novo Nordisk net profit margin as of June 30, 2019 is 32.16%.
Novo Nordisk Annual Profit Margins
Novo Nordisk Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $117.216B $17.724B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $345.150B 15.03
Roche Holding AG (RHHBY) Switzerland $236.204B 0.00
Merck (MRK) United States $211.513B 17.39
Pfizer (PFE) United States $204.151B 12.02
Novartis AG (NVS) Switzerland $199.581B 17.16
AstraZeneca (AZN) United Kingdom $112.218B 21.71
Sanofi (SNY) France $109.456B 13.45
Eli Lilly (LLY) United States $107.057B 19.98
AbbVie (ABBV) United States $104.248B 8.35
GlaxoSmithKline (GSK) United Kingdom $101.988B 12.82
Bristol-Myers Squibb (BMY) United States $80.856B 11.47
Bayer (BAYRY) Germany $70.165B 10.22
H Lundbeck (HLUYY) Denmark $6.958B 10.04